PHARMACON - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 51,553 | 62,878 | 120,007 | 110,258 | 142,762 | 257,096 | 247,077 | 218,515 |
| Profit before tax | 3,067 | -530 | 24,582 | 7,213 | 6,647 | 58,380 | 18,693 | 37,848 |
| Net profit | 2,911 | -530 | 23,371 | 6,465 | 6,294 | 55,467 | 17,879 | 35,574 |
| Equity | 20,643 | 20,113 | 43,484 | 49,949 | 56,243 | 111,710 | 129,590 | 165,164 |
| Liabilities | 42,560 | 50,748 | 65,847 | 32,088 | 27,512 | 32,522 | 34,088 | 16,076 |
| Non-current assets | 86 | 454 | 8,011 | 8,807 | 7,080 | 4,685 | 2,751 | 1,546 |
| Current assets | 62,811 | 70,190 | 100,879 | 72,707 | 86,791 | 139,547 | 160,927 | 179,694 |
| Total assets | 62,897 | 70,644 | 108,890 | 81,514 | 93,871 | 144,232 | 163,678 | 181,240 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 41,859 | 52,727 | 36,289 |
| Social insurance contributions | - | - | - | - | - | - | 2,077 | 1,006 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -6.9% | +22.0% | +90.9% | -8.1% | +29.5% | +80.1% | -3.9% | -11.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 4.6% | -0.8% | 21.5% | 7.9% | 6.7% | 38.5% | 10.9% | 19.6% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 14.1% | -2.6% | 53.7% | 12.9% | 11.2% | 49.7% | 13.8% | 21.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 5.6% | -0.8% | 19.5% | 5.9% | 4.4% | 21.6% | 7.2% | 16.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 5.9% | -0.8% | 20.5% | 6.5% | 4.7% | 22.7% | 7.6% | 17.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 2.1 | 2.5 | 1.5 | 0.6 | 0.5 | 0.3 | 0.3 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 21,332 | 31,439 | 60,004 | 50,888 | 53,535 | 110,186 | 67,384 | 55,791 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
PHARMACON - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-05-03 | 2026-05-10 | 8.35 |
| 2026-04-20 | 2026-04-29 | 8.35 |
| 2026-04-09 | 2026-04-09 | 8.35 |
| 2024-06-18 | 2024-06-30 | 238.88 |
| 2024-03-18 | 2024-03-24 | 680.23 |
| 2023-11-23 | 2023-12-13 | 0.20 |
| 2023-11-16 | 2023-11-22 | 680.61 |
| 2023-10-17 | 2023-11-15 | 0.20 |
| 2023-09-18 | 2023-10-11 | 0.20 |
| 2023-08-17 | 2023-08-24 | 525.42 |
| 2023-06-16 | 2023-06-26 | 525.62 |
| 2023-05-16 | 2023-05-23 | 521.79 |
| 2023-04-18 | 2023-04-25 | 489.31 |
| 2023-03-16 | 2023-03-23 | 520.96 |
| 2023-02-17 | 2023-03-15 | 0.21 |
| 2023-02-06 | 2023-02-14 | 0.21 |
| 2023-01-26 | 2023-02-03 | 0.21 |
| 2023-01-24 | 2023-01-25 | 726.65 |
| 2023-01-17 | 2023-01-23 | 726.44 |
| 2022-11-21 | 2022-12-13 | 0.07 |
| 2022-10-28 | 2022-11-18 | 0.07 |
| 2022-01-18 | 2022-02-09 | 2.03 |
| 2021-12-16 | 2022-01-13 | 2.03 |
| 2021-11-29 | 2021-12-09 | 2.03 |
PHARMACON - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-01-22 | 2026-01-24 | 1.04 |
| 2026-01-01 | 2026-01-21 | 1.09 |
| 2025-10-30 | 2025-11-25 | 0.05 |
| 2025-09-28 | 2025-10-25 | 0.05 |
| 2025-08-28 | 2025-09-25 | 0.05 |
| 2025-07-28 | 2025-08-25 | 0.05 |
| 2025-06-28 | 2025-07-26 | 0.05 |
| 2025-06-19 | 2025-06-25 | 0.05 |
| 2025-04-30 | 2025-05-24 | 3.25 |
| 2025-04-28 | 2025-04-29 | 3655.28 |
| 2025-04-18 | 2025-04-27 | 0.28 |
| 2025-03-28 | 2025-04-17 | 0.33 |
| 2024-12-30 | 2025-01-24 | 0.03 |
| 2024-11-28 | 2024-12-28 | 2.03 |
| 2024-11-01 | 2024-11-25 | 2.03 |
| 2024-09-29 | 2024-10-16 | 0.45 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
PHARMACON, UAB (code 121438323) is a private limited liability company engaged in the wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated revenue of €218.5K and net profit of €35.6K, corresponding to a profit margin of 16.3%. Revenue declined from €257.1K in 2023 to €247.1K in 2024 and then to €218.5K in 2025, while profit moved from €55.5K in 2023 to €17.9K in 2024 before recovering in 2025. The balance sheet strengthened further in 2025, with total assets of €181.2K, equity of €165.2K and liabilities of €16.1K. The equity ratio remained high at 91.1%, and debt to equity was 0.10. Profitability indicators were solid, with ROE at 21.5% and ROA at 19.6%. Asset turnover stood at 1.21x. Revenue per employee was €72.8K and profit per employee was €11.9K, indicating moderate operating productivity.